| Yselty (linzagolix) / Kissei, Syneos Health |
NCT04335591 / 2019-002410-39: Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) |
|
|
| Completed | 3 | 356 | Europe, US, RoW | 75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo capsule to match Add-back capsule | Kissei Pharmaceutical Co., Ltd. | Endometriosis | 09/22 | 12/22 | | |
NCT05620355: Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids. |
|
|
| Recruiting | 3 | 312 | RoW | BG2109, Placebo for BG2109, Placebo for add-back therapy, Add-back therapy | Bio Genuine (Shanghai) Biotech Co., Ltd. | Uterine Fibroids, Heavy Menstrual Bleeding | 05/24 | 03/25 | | |
NCT05894135: Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis |
|
|
| Recruiting | 3 | 540 | RoW | BG2109 100mg, BG2109 200mg, ABT(E2 1 mg / NETA 0.5 mg), BG2109 100mg Placebo, BG2109 200mg Placebo, ABT Placebo | Bio Genuine (Shanghai) Biotech Co., Ltd. | Endometriosis, Moderate to Severe Endometriosis-associated Pain | 06/24 | 03/25 | | |
NCT05445167: A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain |
|
|
| Active, not recruiting | 3 | 78 | Japan | KLH-2109, Placebo | Kissei Pharmaceutical Co., Ltd. | Uterine Fibroids (MeSH Heading: Leiomyoma) | 09/24 | 09/24 | | |
NCT05440383: A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia |
|
|
| Active, not recruiting | 3 | 264 | Japan | KLH-2109, Leuprorelin | Kissei Pharmaceutical Co., Ltd. | Uterine Fibroids (MeSH Heading: Leiomyoma) | 05/25 | 05/25 | | |
| Ongoing | 2 | 0 | RoW | KLH-2109 | KISSEI | Uterine Leiomyoma | | | | |
2017-004043-21: A pilot study to assess the efficacy and safety of OBE2109 in subjects with rectovaginal endometriosis. |
|
|
| Not yet recruiting | 2 | 9 | Europe | OBE2109, OBE2109, Film-coated tablet | ObsEva SA, ObsEva SA | Rectovaginal endometriosis, Rectovaginal endometriosis, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
NCT05738382: Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures |
|
|
| Not yet recruiting | 2 | 240 | RoW | BG2109, Cetrorelix, Cetrorelix Acetate | Bio Genuine (Shanghai) Biotech Co., Ltd. | Assisted Reproductive Technology, Controlled Ovarian Hyperstimulation | 06/24 | 12/24 | | |
| Tavalisse (fostamatinib) / Rigel |
NCT04132050: A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 |
|
|
| Completed | 3 | 34 | Japan | R788, Placebo | Kissei Pharmaceutical Co., Ltd. | Idiopathic Thrombocytopenic Purpura | 12/21 | 09/23 | | |
NCT04629703: Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects |
|
|
| Completed | 3 | 280 | US, RoW | Fostamatinib, Fostamatinib disodium, Placebo | Rigel Pharmaceuticals | Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral | 09/22 | 09/22 | | |
NCT04138927 / 2019-001882-34: A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
|
|
| Enrolling by invitation | 3 | 90 | Europe, US, RoW | Fostamatinib disodium, R935788, Fostamatinib | Rigel Pharmaceuticals | Warm Antibody Autoimmune Hemolytic Anemia | 04/24 | 04/24 | | |
2022-000715-31: Novel Experimental COVID Therapies Affecting Host Response (NECTAR) |
|
|
| Not yet recruiting | 2/3 | 800 | Europe | Fostamatinib, [Non applicabile], Film-coated tablet | NEAT ID, NEAT ID Foundation, National Institutes of Health (NIH) | COVID-19 viral infection Infección por el virus COVID-19, COVID-19 viral infection Infección por el virus COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 2/3 | 871 | US | TXA127, TRV027, Placebo, Fostamatinib | Sean Collins, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) | COVID-19, SARS-CoV-2 Infection, Coronavirus Infection | 10/23 | 12/23 | | |
NECTAR, NCT05593770: International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response |
|
|
| Terminated | 2/3 | 28 | Europe, RoW | Fostamatinib, Placebo | NEAT ID Foundation | COVID-19, SARS-CoV2 Infection, Coronavirus Infection | 12/23 | 12/23 | | |
NCT04543279: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia |
|
|
| Terminated | 2 | 3 | US | Fostamatinib, Tavalisse, Ruxolitinib, Jakafi | Washington University School of Medicine, Rigel Pharmaceuticals | Myelofibrosis, Thrombocytopenia | 07/22 | 07/22 | | |
NCT05040698: Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa |
|
|
| Completed | 2 | 20 | RoW | Fostamatinib, Tavalisse, R935788 | Holdsworth House Medical Practice, Rigel Pharmaceuticals | Hidradenitis Suppurativa | 01/23 | 01/23 | | |
| Not yet recruiting | 2 | 40 | NA | Placebo, Fostamatinib, fostamatinib disodium | Inova Health Care Services, Rigel Pharmaceuticals, Biomedical Advanced Research and Development Authority | Acute Respiratory Distress Syndrome, ARDS | 08/25 | 10/25 | | |
NCT05502783: Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias |
|
|
| Recruiting | 2 | 20 | US | fostamatinib | National Heart, Lung, and Blood Institute (NHLBI) | Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD | 04/26 | 04/26 | | |
NCT05509582: Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias |
|
|
| Enrolling by invitation | 2 | 20 | US | fostamatinib | National Heart, Lung, and Blood Institute (NHLBI) | Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD | 12/28 | 12/28 | | |
| Recruiting | 1/2 | 456 | Europe | Ruxolitinib, Fostamatinib, Standard of care | Imperial College London, Imperial College Healthcare NHS Trust, Rigel Pharmaceuticals, Novartis | Coronavirus, Covid19, Pneumonia | 06/22 | 06/22 | | |
| Active, not recruiting | 1/2 | 8 | Europe | Fostamatinib, Spleen Tyrosine Kinase Inhibitor, TAVALISSE | Imperial College London | Renal Transplant Rejection | 04/23 | 10/25 | | |
NCT02611063: Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant |
|
|
| Completed | 1 | 22 | US | fostamatinib | Stefanie Sarantopoulos, MD, PhD. | Hematological Malignancies | 02/21 | 02/22 | | |
NCT03246074: Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer |
|
|
| Completed | 1 | 35 | US | Fostamatinib 100 mg bid and Paclitaxel, Fostamatinib and Abraxane, Fostamatinib 150 mg bid and Paclitaxel, Fostamatinib 200 mg bid and Paclitaxel | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Rigel Pharmaceuticals, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Ovarian Cancer | 08/22 | 04/23 | | |
NCT05904093: Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease |
|
|
| Enrolling by invitation | 1 | 25 | US | Fostamatinib | National Heart, Lung, and Blood Institute (NHLBI) | Sickle Cell Disease, Hb-SS Disease, Hemoglobin S, Disease Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin Beta Thalassemia Disease | 08/25 | 05/26 | | |
NCT06233110: Ruxolitinib Plus Fostamatinib for Steroid Refractory CGvHD |
|
|
| Not yet recruiting | 1 | 30 | US | Fostamatinib, Ruxolitinib | Stefanie Sarantopoulos, MD, PhD., Incyte Corporation, Rigel Pharmaceuticals, National Institutes of Health (NIH) | Chronic Graft Versus Host Disease | 01/29 | 07/29 | | |
NCT06639724: Perioperative Fostamatinib with Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer |
|
|
| Not yet recruiting | 1 | 36 | NA | Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) | University of California, San Diego, Rigel Pharmaceuticals | Pancreatic Ductal Adenocarcinoma (PDAC) | 06/27 | 12/28 | | |
NCT05030675: Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents |
|
|
| Completed | 1 | 11 | US | Fostamatinib, R-935788 Free Acid, R788 Free Acid | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome | 08/24 | 08/24 | | |
NCT03363334: Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP |
|
|
| No Longer Available | N/A | | NA | Fostamatinib disodium 100 mg, Fostamatinib, R935788, R788, Fostamatinib disodium 150 mg | Rigel Pharmaceuticals | Immune Thrombocytopenic Purpura | | | | |
FORTE, NCT04904276: Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy |
|
|
| Terminated | N/A | 16 | US | Fostamatinib | Rigel Pharmaceuticals | ITP, Immune Thrombocytopenia | 11/22 | 11/22 | | |
NCT06071520: Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study |
|
|
| Completed | N/A | 50 | Europe | Fostamatinib, Andalusian PTI fostamatinib patients | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Primary Immune Thrombocytopenia | 04/23 | 06/23 | | |
ChiCTR2000033293: Clinical study of efficacy and safety of flumatinib combined with autologous hematopoietic stem cell transplantation in the treatment of Ph+ acute lymphoblastic leukemia |
|
|
| Recruiting | N/A | 42 | | Fostamatinib combined with autologous hematopoietic stem cell transplantation | The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University, self-raised | acute lymphoblastic leukemia | | | | |
NCT05613296: Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP |
|
|
| Not yet recruiting | N/A | 47 | NA | Fostamatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | ITP - Immune Thrombocytopenia, Chronic ITP, Refractory ITP | 12/23 | 12/23 | | |
| Actemra IV (tocilizumab) / Roche, JW Pharma |
| Ongoing | 4 | 180 | Europe | MabThera, RoActemra, L01X CO2, L04AC07, Concentrate for solution for infusion, MabThera, RoActemra | Joint Research & Development Office (Barts and The London School of Medicine & Dentistry), Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London, , Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London, ECAM Clinical Academic Group Barts Health NHS Trust, Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) | Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2015-000863-15: RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE + BIOLOGIC VERSUS METHOTREXATE, SALAZOPYRINE AND HYDROXYCHLOROQUINEIN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE |
|
|
| Not yet recruiting | 4 | 286 | Europe | L04AB01, Powder and solution for solution for injection, Solution for injection, Concentrate for solution for infusion, Solution for infusion, Concentrate for solution for injection, Tablet, Powder and solvent for solution for injection, ENBREL, HUMIRA, REMICADE, ORENCIA, SIMPONI, CIMZIA, ROACTEMRA, MABTHERA, SALAZOPYRINE, IMETH, METOJECT, PLAQUENIL | Hôpitaux Universitaires de Strasbourg, Ministry of Health | RHEUMATOID ARTHRITIS, PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE, Diseases [C] - Immune System Diseases [C20] | | | | |
2010-018696-21: Etude de l’évolution de la réponse immunitaire Th17 chez des patients atteints de polyarthrite rhumatoïde et traités par tocilizumab après échec des autres thérapies |
|
|
| Ongoing | 4 | 15 | Europe | TOCILIZUMAB, RoACTEMRA, RoACTEMRA | CHU DIJON | Polyarthrite rhumatoïde | | | | |
2012-004482-40: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluación de un protocolo para la disminución de dosis en pacientes con Artritis Reumatoide (AR) en remisión clínica en tratamiento con terapias biológicas |
|
|
| Ongoing | 4 | 28 | Europe | Infliximab, Adalimumab, Etanercept, Certolizumab Pegol, Golimumab, Abatacept, Tocilizumab, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra | FRANCISCO J. BLANCO GARCÍA, FRANCISCO J. BLANCO GARCIA | Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis in clinical remission at treatment with biologic therapies Evaluación de la utilidad clínica de un protocolo estandarizado de estrategias para la disminución de dosis en pacientes con Artritis Reumatoide en remisión clínica a tratamiento con terapias biológicas | | | | |
ChiCTR-OPC-17011391: The efficacy and safety of tocilizumab for refractory systemic juvenile idiopathic arthritis in China |
|
|
| Completed | 4 | 60 | | tocilizumab ;glucocorticoid | Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University, Chongqing Science and Technology Commission | systemic juvenile idiopathic arthritis | | | | |
2015-000833-64: Comparaison de trois biomédicaments en termes d’évolution des sous-populations lymphocytaires régulatrices et pro-inflammatoires chez des patients atteints de polyarthrite rhumatoïde. |
|
|
| Not yet recruiting | 4 | 110 | Europe | Powder for concentrate for solution for injection/infusion, Solution for infusion, ORENCIA, MABTHERA, ROACTEMRA | CHU Amiens-Picardie | Rheumatoid arthritis polyarthrite rhumatoïde, Rheumatoid arthritis Polyarthrite rhumatoïde, Diseases [C] - Immune System Diseases [C20] | | | | |
2017-001970-41: Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trial |
|
|
| Ongoing | 4 | 180 | Europe | Abatacept, Adalimumab, Certolizumab pegol, Etanercept, Golimumab, Infliximab, Tocilizumab, L04AA24, L04AB04, L04AB05, L04AB01, L04AB06, L04AB02, L04AC07, Concentrate for solution for injection, Concentrate and solvent for solution for infusion, Concentrate and solvent for solution for injection, Concentrate and solvent for suspension for injection, Orencia, Humira, Cimzia, Enbrel, Benepali, Simponi, Remsima, Remicade, RoActemra, Inflectra, Imraldi, Amgevita | MD, PhD Salome Kristensen, The Danish Regions (Regionernes Medicinpulje), The Department of Rheumatology at Aalborg University Hospital, Health Science Research Fund of the Region of Northern Jutland | Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (arthritis of the spine), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Not yet recruiting | 4 | 18 | | Tocilizumab treatment group | Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital; Peking Union Medical College Hospital, “863” Project of Ministry of Science and Technology | Takayasu's arteritis | | | | |
ChiCTR1800015472: A single arm,single-center clinical study of tocilizumab in the treatment of corticosteroids unresponsive pre-engraftment syndrome patients after unrelated cord blood transplantation |
|
|
| Recruiting | 4 | 10 | | Tocilizumab | Anhui Provincial Hospital; Anhui Provincial Hospital, National Natural Science Foundation of China | hematologic malignancies patients with PES after umbilical cord blood transplantation | | | | |
2017-003037-28: Efficacy of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease modifying anti-rheumatic drugs. |
|
|
| Not yet recruiting | 4 | 120 | Europe | Prednisone, Solution for injection/infusion in pre-filled syringe, Tablet, RoActemra, Prednisone | University Medical Center Utrecht, University Medical Center Utrecht, Roche | RA patients with active RA despite treatment with DMARDs. Reumatoïde artritis, RA patients with active RA despite treatment with DMARDs. Reuma (reumatoïde artritis), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-001754-25: Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment |
|
|
| Not yet recruiting | 4 | 84 | Europe | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab, Injection, Enbrel, Benepali, Erelzi Rituximab: mabthera, Rixathon, Truxima Abatacept: Orencia Tocilizumab: Roactemra Sarilumab: Kevzara | Reade, ZonMw | rheumatoid arthritis, Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
ChiCTR2000033705: A medical records based study for the preliminary efficacy of Tocilizumab in the treatment of the patients with novel coronavirus pneumonia (COVID-19) |
|
|
| Completed | 4 | 61 | | Tocilizumab ;routine treatment protocol | Xijing Hospital; Xijing Hospital, the Key Research and Development Project of Shaanxi Province of China (grant number 2020ZDXM-SF-002) and Natural Science Foundation of Shaanxi Province of China (grant number 2019JM-465). | Novel Coronavirus Pneumonia (COVID-19) | | | | |
2020-001437-12: Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs ENSAYO CLÍNICO ALEATORIZADO, CONTROLADO, ABIERTO, UNICÉNTRICO, DE TRATAMIENTO INMUNOMODULADOR EN PACIENTES ADULTOS CON NEUMONIA GRAVE COVID-19 |
|
|
| Ongoing | 4 | 290 | Europe | RoActemra, Concentrate for solution for infusion, Capsule, soft, Sandimmun, RoActemra | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | Severe COVID-19 pneumonia Neumonía grave COVID-19, Severe COVID-19 pneumonia Neumonía grave COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR2000029765: A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19) |
|
|
| Recruiting | 4 | 188 | | conventional therapy ;conventional therapy+tocilizumab | The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital), Department of science and technology of Anhui Province | new coronavirus pneumonia | | | | |
ChiCTR2000030894: Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial |
|
|
| Recruiting | 4 | 150 | | Favipiravir Combined With Tocilizumab ;Favipiravir ;Tocilizumab | Peking University First Hospital; Peking University First Hospital, self-financed | Novel Coronavirus Pneumonia (COVID-19) | | | | |
2019-004302-10: A clinical trial to study Tocilizumab for treatment of chronic rejection due to antibodies in kidney transplant patients |
|
|
| Not yet recruiting | 4 | 50 | Europe | Solution for injection in pre-filled pen, RoActemra | Västra Götalandsregionen, Sahlgrenska University hospital, Vetenskapsrådet | Treatment of chronic active antibody-mediated rejection in kidney transplant recipients, Treatment of chronic kidney transplant rejection due to antibodies, Body processes [G] - Immune system processes [G12] | | | | |
ChiCTR-OPB-17013704: A phase IV, multicenter single-arm, open-label study to assess the efficecy and safety of Tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis |
|
|
| Recruiting | 4 | 65 | | Tocilizumab | Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University, Drug clinical trial bid party (Shanghai Roche Pharmaceuticals Ltd.) | systemic juvenile idiopathic arthritis | | | | |
NCT04779047: Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients. |
|
|
| Recruiting | 4 | 150 | RoW | Remdesivir, Hydroxychloroquine, Tocilizumab, Actemra, Lopinavir/ Ritonavir, kaletra, Ivermectin, Iverazine | October 6 University, Beni-Suef University | Covid19, Pneumonia | 03/21 | 04/21 | | |
| Recruiting | 4 | 98 | Europe | Tocilizumab | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development | Rheumatoid Arthritis | 12/24 | 12/24 | | |
ADDORA-switch, NCT04251741: Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment |
|
|
| Active, not recruiting | 4 | 86 | Europe | Adalimumab trough concentration, Usual care | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development, Sint Maartenskliniek | Rheumatoid Arthritis | 05/24 | 05/24 | | |
NCT04300686: A Pilot Study in Severe Patients With Takayasu Arteritis. |
|
|
| Recruiting | 4 | 40 | RoW | Tocilizumab, IL-6R alpha antibody, Adalimumab, TNF-alpha antibody | Shanghai Zhongshan Hospital | Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment | 05/22 | 12/23 | | |
ChiCTR2000032678: A multicenter, non-interventional, prospective study of the safety and efficacy of tocilizumab in the treatment of rheumatoid arthritis in the real world |
|
|
| Not yet recruiting | 4 | 2500 | | N/A | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shanghai Roche Pharmaceutical Co., Ltd. | RA | | | | |
NCT04762784: A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis |
|
|
| Recruiting | 4 | 40 | RoW | Tocilizumab, Glucocorticoids | Peking Union Medical College Hospital | Idiopathic Retroperitoneal Fibrosis | 02/23 | 02/23 | | |
| Active, not recruiting | 4 | 812 | Europe, RoW | Non-biological DMARD's, Cimzia, Orencia, RoActemra | Karolinska Institutet | Rheumatoid Arthritis | 07/23 | 12/23 | | |
NCT05730777: Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics |
|
|
| Not yet recruiting | 4 | 200 | RoW | Bifidobacterium Bifidum Oral Capsule, Probiotics, Cisplatin, conventional antitumor treatmen, Carboplatin, Paclitaxel, Atlizumab | Peking University Third Hospital | Cancer Therapy-related Cardiovascular Toxicity | 07/23 | 12/23 | | |
| Active, not recruiting | 4 | 25 | Europe | Sulphasalazine + Hydroxychloroquine OR Prednisolone, SSZ+HCQ or Prednisolone, Cimzia, Certolizumab-pegol, Orencia, Abatacept, RoActemra, Tocilizumab | Karolinska Institutet | Rheumatoid Arthritis | 07/23 | 12/23 | | |
ChiCTR2100044103: Epirubicin-loaded microspheres TACE combined with tocilizumab in the treatment of stage III hepatocellular carcinoma |
|
|
| Recruiting | 4 | 156 | | DEB-TACE ;DEB-TACE combined with IL-6 antibody | Qingdao University Affiliated Hospital; Qilu Hospital of Shandong University, Beijing Medical Award Foundation | Primary liver cancer | | | | |
NCT05604859: Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS) |
|
|
| Recruiting | 4 | 350 | RoW | Methylprednisolone, intravenous immunoglobulin, Tocilizumab, Low molecular weight heparin, conventional treatment | Qin Ning | Severe Fever With Thrombocytopenia Syndrome | 12/23 | 06/24 | | |
NCT06498089: A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis |
|
|
| Recruiting | 4 | 124 | RoW | Prednisone, Glucocorticoids, Methotrexate, MTX, Tocilizumab, TCZ, Tofacitinib, TOF, Adalimumab, ADA | Shanghai Zhongshan Hospital | Takayasu Arteritis | 06/26 | 06/27 | | |
NCT05855122: Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients |
|
|
| Recruiting | 4 | 48 | RoW | Tocilizumab | The First Affiliated Hospital of Soochow University | Multiple Myeloma | 08/24 | 12/24 | | |
DEDICATE-LPS, NCT06624436: Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia |
|
|
| Not yet recruiting | 4 | 52 | Europe | Dexamethasone, Tocilizumab, RoActemra, Tyenne, Anakinra, Kineret, Placebo, NaCl 0.9%, LPS, Endotoxin, Lipopolysaccharide (LPS from E. coli type O113) | Radboud University Medical Center | Sepsis, Neuroinflammatory Response, Immunosuppresion, Endotoxemia, Anakinra, Dexamethasone, Tocilizumab | 05/25 | 07/25 | | |
NCT06251076: Plan Development for Giving Teclistamab in the Outpatient Setting |
|
|
| Not yet recruiting | 4 | 15 | NA | Teclistamab, TECVAYLI, Tocilizumab, ACTEMRA | University Health Network, Toronto, Janssen Inc. | Multiple Myeloma, Relapsed Cancer, Refractory Cancer | 04/25 | 09/25 | | |
BIO3, NCT02714634: Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide |
|
|
| Recruiting | 4 | 286 | Europe | Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration | University Hospital, Strasbourg, France | Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide | 03/25 | 03/25 | | |
ACTRN12614000266662: Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD) randomized trial |
|
|
| Recruiting | 3 | 110 | | | Royal Brisbane and Women's Hospital, National Health & Medical Research Council | Acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT) | | | | |
2014-003529-16: Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology |
|
|
| Ongoing | 3 | 219 | Europe | MabThera, RoActmera, Enbrel, Concentrate for solution for infusion, Solution for injection, Solution for injection in pre-filled pen, MabThera, RoActmera, Enbrel | Joint Research & Development Office (QMUL), Medical Research Council, Arthritis Research UK | Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2015-005389-51: Safety and Efficacy of tocilizuMAb versus placebo in Polymyalgia rHeumatica with glucocORticoid dEpendence SEMAPHORE |
|
|
| Ongoing | 3 | 100 | Europe | RoActemra, Concentrate and solvent for solution for infusion, Tocilizumab | CHRU DE BREST, Laboratoire CHUGAI | Polymyalgia rHeumatica, Inflammatory disease in the elderly, Diseases [C] - Immune System Diseases [C20] | | | | |
2017-004079-30: Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology |
|
|
| Ongoing | 3 | 219 | Europe | MabThera, RoActmera, Enbrel, Concentrate for solution for infusion, Solution for injection, Solution for injection in pre-filled pen, MabThera, RoActmera, Enbrel | Joint Research & Development Office (QMUL), AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA, Medical Research Council, Arthritis Research UK, Queen Mary University of London (QMUL) | Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2014-003484-38: Evaluation de l'efficacité du Tocilizumab dans l'arthrose digitale invalidante et réfractaire aux traitements usuels |
|
|
| Not yet recruiting | 3 | 90 | Europe | RoActemra, EMEA/H/C/000955, Concentrate for solution for injection, Roche Registration Limited | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Patients atteints d'arthrose digitale (IPD et IPP) selon les critères de l'ACR symptomatique (douleur au moins 1 jour sur 2 dans le dernier mois) évoluant depuis plus de 3 mois, patients souffrant d'une arthrose digitale invalidante et réfractaire aux traitements usuels, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2018-002826-22: Comparaison entre le Méthotrexate et le Tocilizumab pour le traitement de l'artérite à cellules géantes |
|
|
| Not yet recruiting | 3 | 200 | Europe | Solution for injection, Solution for injection in pre-filled syringe, METOJECT, RoActemra | CHU Dijon Bourgogne | Artérite à cellules géantes, Maladie de Horton, Diseases [C] - Immune System Diseases [C20] | | | | |
2020-001903-17: Effects of Tocilizumab and its combination with Vitamin D to treat the increased defensive response in COVID-19 Efecto de Tocilizumab y su combinación con Vitamina D para el tratamiento de la respuesta defensiva aumentada al COVID-19 |
|
|
| Ongoing | 3 | 120 | Europe | Tocilizumab (Actemra/RoActemra)™ , Roche, VITAMINE D3 BON 200 000 U.I./1 ml, solution injectable, L04AC07, A11CC05, Solution for injection/infusion, Solution for injection, Tocilizumab (Actemra/RoActemra)™ , Roche, VITAMINE D3 BON 200 000 U.I./1 ml, solution injectable IM en ampoule, boîte de 1 ampoule | HOSPITAL UNIVERISTARIO DE MOSTOLES, SERMAS | COVID INFECTION IS A MILD FLU LIKE CONDITION WITH MILD FEVER, DRY COUGH, WIDESPREAD TENDERNESS AND OLFACTORY DISFUNCTION FOLLOWED BY A SERIOUS SITUATION IN SOME 20% OF PATIENTS WITH OVERT FEVER, MALAISE, CHILLS AND DYSPNEA DUE TO HYPERIMMUNE RESPONSE. OXYGEN IS LIKELY TO BE GIVEN IN ABOUT 70% OF PATIENTS AND MORTALITY RATE VARIES FROM 10 TO 40% OF SEVERE CASES. LA INFECCION POR COVID ES UNA ESPECIE DE GRIPE CON FEBRICULA, TOS SECA,DOLORES DIFUSOS Y ALTERACIÓN OLFATIVA SEGUIDAD DE UN CUADRO GRAVE 820% DE PACIENTES) CON FIEBRE FRANCA, MALESTAR GENERAL, ESCALOFRIOS Y DISNEA DEBIDA A UNA HIPERRESPUESTA INMUNE.SERA NECESARIO OXIGENOTERAPIA EN UN 70% DE PACIENTES Y LA MORTALIDAD OSCILA ENTRE EL 10 Y EL 40% DE LOS CASOS GRAVES., CORONAVIRUS IS A FLU LIKE STATE WITH MILD FEVER , COUGH AND MILD PAIN IN LIMBS THAT LATER ON SHOWS HIGH FEVER, PAIN AND DIFFICULTY TO BREATHE WITH OXYGEN NEEDS DUE TO INCREASED DEFENSIVE RESPONSE. EL CORONAVIRUS ES UNA ESPECIE DE GRIPE CON FIEBRE BAJA, TOS Y MOLESTIAS QUE DESPUES DA FIEBRE ALTA, DOLOR Y DIFICULTAD PARA RESPIRAR CON NECESIDAD DE OXIGENO POR UNA RESPUESTA DEFENSIVA EXAGERADA, Diseases [C] - Virus Diseases [C02] | | | | |
2020-001707-16: PHASE III RANDOMIZED, UNICENTRIC OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION ENSAYO CLÍNICO ALEATORIZADO, UNICENTRICO, ABIERTO, CONTROLADO, EN FASE III, PARA DEMOSTRAR LA EFECTIVIDAD DE TOCILIZUMAB FRENTE A CORTICOTERAPIA SISTÉMICA EN PACIENTES INGRESADOS POR COVID-19 CON NEUMONÍA BILATERAL Y MALA EVOLUCIÓN |
|
|
| Ongoing | 3 | 60 | Europe | tocilizumab, Metilprednisolona, Concentrate for solution for infusion, Solution for injection/infusion, Roactemra, Urbason | IIS BIODONOSTIA, IIS BIODONOSTIA | bilateral SARS-CoV-2 pneumonia with poor clinical course neumonía bilateral por SARS- CoV-2 con mala evolución clínica, bilateral SARS-CoV-2 pneumonia with poor clinical course neumonía bilateral por SARS- CoV-2 con mala evolución clínica, Diseases [C] - Virus Diseases [C02] | | | | |
EMPACTA, NCT04372186: A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia |
|
|
| Completed | 3 | 377 | US, RoW | Placebo, Tocilizumab | Genentech, Inc. | COVID-19 Pneumonia | 08/20 | 09/20 | | |
|
TRONCHER, NCT04361032: Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia |
|
|
| Not yet recruiting | 3 | 260 | RoW | Tocilizumab Injection, ROACTEMRA, Deferoxamine, DESFERAL | Abderrahmane Mami Hospital, Eshmoun Clinical Research Centre, Datametrix | COVID19, Intensive Care Unit | 09/20 | 10/20 | | |
2016-000312-15: Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic Arthritis with inactive disease on biologic therapy Décroissance thérapeutique dans l'arthrite juvénile idiopathique oligoarticulaire ou polyarticulaire sans facteur rhumatoïde en maladie inactive sous biothérapie. |
|
|
| Not yet recruiting | 3 | 230 | Europe | ENBREL, HUMIRA, ROACTEMRA, ORENCIA, Cutaneous solution, Solution for injection, ENBREL, HUMIRA, ROACTEMRA, ORENCIA | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS | Patients with oligoarticular onset or rheumatoid factor negative polyarticular JIA followed in tertiary care center for paediatric rheumatology. | | | | |
2018-002202-31: A Phase 3 study to compare BAT1806 with RoActemra in patients with Rheumatoid Arthritis |
|
|
| Not yet recruiting | 3 | 621 | Europe | RoActerma, BAT1806, Infusion, RoActemra | Bio-Thera Solutions, Ltd., Bio-Thera Solutions, Ltd. | Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate, Rheumatoid Arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
2020-005291-35: A multicenter randomized trial to evaluate the efficacy of tocilizumab in patients with severe Coronavirus Disease 2019 (Covid-19) pneumonia failing glucocorticoids. Studio multicentrico randomizzato per valutare l'efficacia di tocilizumab in pazienti con polmonite severa da Coronavirus 2019 (Covid-19) che falliscono la terapia con glucocorticoidi. |
|
|
| Ongoing | 3 | 640 | Europe | tocilizumab, [DB06273], Concentrate for solution for infusion | AOU POLICLINICO DI MODENA, Regione Emilia Romagna, Fondazione Cassa di Risparmio di Modena | polmonite severa da coronavirus 2019 severe Coronavirus Disease 2019, polmonite severa da coronavirus 2019 severe Coronavirus Disease 2019, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04693026: Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients |
|
|
| Recruiting | 3 | 150 | RoW | Remdesivir, Ninavir, Baricitinib, Tocilizumab | M Abdur Rahim Medical College and Hospital, First affiliated Hospital Xi'an Jiaoting University | Covid19, Covid-19 ARDS | 02/21 | 03/21 | | |
2020-002275-34: A controlled study on the safety and efficacy of the combination remdesivir plus tocilizumab compared with individual use of these drugs for treatment of severe COVID-19 pneumonia in hospitalized patients Un estudio controlado sobre la seguridad y eficacia de la combinación remdesivir más tocilizumab en comparación con el uso individual de estos fármacos para el tratamiento de la neumonía grave por COVID-19 en pacientes hospitalizados. |
|
|
| Not yet recruiting | 3 | 800 | Europe | Actemra, Remdesivir, RO4877533/F03-01, RO7286260/F01, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Actemra®/ RoActemra®, Veklury® | F. Hoffman-La Roche Ltd., F. Hoffmann-La Roche Ltd. | Severe coronavirus disease 2019 (COVID-19) pneumonia Neumonía grave por COVID-19, Severe lower respiratory tract infection caused by a new type of coronavirus. Infección grave del tracto respiratorio inferior causada por un nuevo tipo de coronavirus., Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR2300067652: A Phase III clinical study to compare the safety and efficacy of LZM008 injection and ACTEMRA in patients with moderate to severe active rheumatoid arthritis (RA) |
|
|
| Completed | 3 | 640 | | LZM008, 8 mg/kg, administrated once every 4 weeks and in combination with methotrexate (7.5-25mg/week) ;Tocilizumab Injection (ACTEMRA?), 8 mg/kg, administrated once every 4 weeks and in combination with methotrexate (7.5-25mg/week) | Huashan Hospital, Fudan University / Peking University, Reople’s Hospital; Livzon Mabpharm Inc., Livzon Mabpharm Inc. | Moderate to severe active rheumatoid arthritis | | | | |
NCT04423042: Tocilizumab in Coronavirus-19 Positive Patients |
|
|
| Not yet recruiting | 3 | 30 | NA | Tocilizumab, Actemra | University of Calgary | Covid19, COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus, Inflammation | 06/21 | 06/21 | | |
2020-002039-31: Use of Tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease |
|
|
| Not yet recruiting | 3 | 90 | Europe | RoActemra, Infusion, RoActemra | Turku University Hospitla | COVID-19 / new coronavirus disease, new coronavirus disease (COVID-19), Diseases [C] - Virus Diseases [C02] | | | | |
NCT05002517: Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab |
|
|
| Active, not recruiting | 3 | 60 | Europe | Tociliziumab group, Methylprednisolone group | Asociacion Instituto Biodonostia | COVID-19 Pneumonia | 07/21 | 10/21 | | |
NCT06048224: Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 669 | RoW | HS628+MTX, Actemra +MTX | Zhejiang Hisun Pharmaceutical Co. Ltd. | Moderate to Severe Active Rheumatoid Arthritis | 09/21 | 01/22 | | |
| Recruiting | 3 | 300 | US | Tocilizumab, Actemra, Placebo | Queen's Medical Centre | COVID-19 | 12/21 | 12/21 | | |
NCT04000698: Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias |
|
|
| Recruiting | 3 | 25 | RoW | Preparative regimen | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Refractory Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia | 07/22 | 12/22 | | |
2022-001066-36: Effects of intravenous infusions of either CT-P47 or RoActemra, as co-administered with methotrexate, in patients with active rheumatoid arthritis Ocena wpływu leczenia CT-P47 lub RoActemrą, podawanych we wlewach dożylnych, u pacjentów z aktywnym reumatoidalnym zapaleniem stawów leczonych metotreksatem |
|
|
| Not yet recruiting | 3 | 448 | Europe | RoActemra 20 mg/mL concentrate for solution for infusion., CT-P47, Concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion. | CELLTRION, Inc., CELLTRION, Inc. | Moderate to severe active rheumatoid arthritis (RA) diagnosed according to the 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria (Aletaha et al., 2010) for at least 24 weeks, who have inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs)., moderate to severe active rheumatoid arthritis (RA), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Not yet recruiting | 3 | 216 | Europe | Anakinra +/- Ruxolitinib (stages 2b/3), Anakinra and Ruxolitinib (Advanced stage 3), Tocilizumab +/- ruxolitinib (stages 2b/3), Tocilizumab and Ruxolitinib (Advanced stage 3), Standard of care | Assistance Publique Hopitaux De Marseille | Covid19 | 09/22 | 11/22 | | |
NCT05489224: A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis |
|
|
| Completed | 3 | 471 | Europe | CT-P47, EU-approved RoActemra | Celltrion | Rheumatoid Arthritis | 06/23 | 11/23 | | |
NCT05346666: Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus. |
|
|
| Recruiting | 3 | 50 | RoW | Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam | Damanhour University, Principal Investigator Sahar El-Haggar, Prof Clinical pharmacy Department- Tanta University, Principal Investigator Mohanad Omar Ahmed, Msc Pharmacy Practice Department- Horus University, Principal Investigator Sahar Hegazy, Prof Clinical pharmacy Department- Tanta University | Epilepsy | 09/23 | 10/23 | | |
| Recruiting | 3 | 70000 | Europe, RoW | Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone | University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab | Severe Acute Respiratory Syndrome | 06/26 | 06/36 | | |
|
NINTOC-TU, NCT06297096: Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease |
|
|
| Not yet recruiting | 3 | 86 | Europe | Tocilizumab, Nintedanib, Standard therapy, mycophenolate mofetil, methotrexate | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland, Medical Research Agency, Poland | Systemic Sclerosis, Interstitial Lung Disease | 12/27 | 03/28 | | |
| Not yet recruiting | 3 | 486 | NA | Tocilizumab, NaCl 0.9% 100ml | Zhujiang Hospital, Shenzhen Second People's Hospital, Central People's Hospital of Zhanjiang, Shantou Central Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, Guangzhou First People's Hospital, Peking University Shenzhen Hospital, Guangdong Provincial People's Hospital | Brain Diseases, Ischemic Stroke, Ischemia, Stroke, Cerebral Infarction, Atherosclerosis of Artery, Atheroscleroses, Intracranial | 12/25 | 06/29 | | |
STARGLO, NCT04408638 / 2020-001021-31: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 270 | Europe, US, RoW | Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin | Hoffmann-La Roche | Diffuse Large B-cell Lymphoma | 04/25 | 04/25 | | |
|
|
|
|
SUNMO, NCT05171647: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma |
|
|
| Active, not recruiting | 3 | 222 | Canada, Japan, US, RoW | Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin | Hoffmann-La Roche | Non-Hodgkin Lymphoma | 02/25 | 02/27 | | |
|
|
| Recruiting | 3 | 50 | Europe | Tocilizumab, RoActemra | Vastra Gotaland Region, Karolinska University Hospital, Uppsala University Hospital, Skane University Hospital, The Swedish Research Council | Antibody-mediated Rejection | | | | |
METOGiA, NCT03892785: MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 3 | 230 | Europe | Prednisone treatment, Tocilizumab treatment, Methotrexate treatment, Questionnaires, Blood samples | Centre Hospitalier Universitaire Dijon | Giant Cell Arteritis | 01/26 | 03/27 | | |
| Recruiting | 3 | 20000 | Europe, Canada, Japan, US, RoW | Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir | UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore | Community-acquired Pneumonia, Influenza, COVID-19 | 02/26 | 02/28 | | |
GLOBRYTE, NCT06084936: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 182 | Europe, Canada, US, RoW | Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab | Hoffmann-La Roche | Lymphoma | 02/26 | 12/26 | | |
